The Global Hemoperfusion Market Size accounted for USD 615.4 Million in 2022 and is estimated to achieve a market size of USD 3,052.1 Million by 2032 growing at a CAGR of 17.5% from 2023 to 2032.
Hemoperfusion Market Highlights
Hemoperfusion is a treatment technique that uses an adsorbent substance such as charcoal or resins to help remove toxic substances from blood in large volumes. The hemoperfusion system is prepared by the process of sterilization of cartridge containing the adsorbent, and rinsing it with heparinized saline solution. The market for hemoperfusion has witnessed significant growth due to rising demand from various applications such as the treatment of liver (hepatic) failure and autoimmune diseases.
Global Hemoperfusion Market Dynamics
Hemoperfusion Market Report Coverage
|Hemoperfusion Market Size 2022||USD 615.4 Million|
|Hemoperfusion Market Forecast 2032||USD 3,052.1 Million|
|Hemoperfusion Market CAGR During 2023 - 2032||17.5%|
|Hemoperfusion Market Analysis Period||2020 - 2032|
|Hemoperfusion Market Base Year||2022|
|Hemoperfusion Market Forecast Data||2023 - 2032|
|Segments Covered||By Adsorption, By Application, And By Geography
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||Jafron Biomedical Co., Ltd., Kaneka Corporation, Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG, Toray Medical Co., Ltd., Asahi Kasei Medical Co., Ltd., NxStage Medical, Inc., CytoSorbents Corporation, and Spectral Medical Inc.
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis|
Hemoperfusion Market Insights
The increasing use of adsorbent substance technique to remove toxic substances and poisons, investment in emerging economies (such as India, China, Brazil, South East-Asia, and Mexico), and high growth in end use industries is driving the market for hemoperfusion, globally. Increased use of hemoperfusion in healthcare such as providing supportive treatment before and after transplantation for patients in case of liver failure and the emergence of new end users of hemoperfusion is expected to change the dynamics of the market in near future. Some of the key challenges include risks such as infection, blood clotting, destruction of blood platelets, and organ failure associated with hemoperfusion restrict the adoption of this technology to a larger extent.
Hemoperfusion Market, By Segmentation
The worldwide market for hemoperfusion is split based on adsorption, application, and geography.
According to a hemoperfusion market analysis, charcoal hemoperfusion is one of the oldest and most commonly used adsorbent materials in hemoperfusion therapy. It has a large surface area and a high capacity for adsorption for a wide variety of toxins and harmful substances, making it useful in the treatment of acute poisoning and other critical care situations.
Certain resins, such as those based on polystyrene or acrylonitrile, are also used in hemoperfusion therapy. When compared to charcoal, these resins have different adsorption properties and may be more effective in removing specific toxins or harmful substances from the bloodstream.
Overall, the selection of adsorbent material is determined by the clinical situation and the preferences of healthcare providers. The hemoperfusion market is being propelled by a number of factors, including an increase in the number of acute poisoning cases, chronic kidney diseases, and technological developments in hemoperfusion devices and consumables.
According to hemoperfusions market forecasts, autoimmune and intoxications are the two most commonly used applications of hemoperfusions. Hemoperfusion therapy is primarily used in critical care settings to remove toxins and harmful substances from the bloodstream in conditions such as acute liver failure, autoimmune diseases, and intoxications. Other applications of hemoperfusion therapy include the treatment of sepsis, cytokine storm syndrome, and drug overdose.
In terms of market size, the hemoperfusion market is primarily driven by the increasing incidence of acute poisoning cases and chronic kidney diseases, as well as the growing demand for hemoperfusion devices and consumables in critical care settings. The market for hemoperfusion devices and consumables is also driven by the availability of different types of adsorbent materials, including charcoal and certain resins, that offer specific advantages for toxin removal in different situations.
Hemoperfusion Market Regional Outlook
The Middle East & Africa
Hemoperfusion Market Regional Analysis
The major markets for hemoperfusion in North America are the United States and Canada. The high prevalence of chronic kidney diseases and acute poisoning cases, as well as a well-established healthcare infrastructure, are some of the key factors driving the growth of this region's hemoperfusion market.
The European hemoperfusion market is divided into two parts: Western Europe and Eastern Europe. Western Europe, which includes countries such as Germany, France, and the United Kingdom, accounts for the majority of Europe's hemoperfusion market share. The rising prevalence of chronic kidney disease, combined with government initiatives to improve healthcare infrastructure, is expected to propel the hemoperfusion market in this region forward.
China, Japan, India, Australia, and the Rest of Asia-Pacific are the regions that make up the Asia-Pacific hemoperfusion market. Because of the increasing incidence of acute poisoning cases and chronic kidney diseases in the region, the Asia-Pacific region is projected to see the fastest growth in the hemoperfusion market. Japan and China are the region's two largest hemoperfusion markets.
Hemoperfusion Market Players
Some of the top hemoperfusion companies offered in the professional report include Jafron Biomedical Co., Ltd., Kaneka Corporation, Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG, Toray Medical Co., Ltd., Asahi Kasei Medical Co., Ltd., NxStage Medical, Inc., CytoSorbents Corporation, and Spectral Medical Inc
The market size of hemoperfusion was USD 615.4 million in 2022.
The CAGR of hemoperfusion is 17.5% during the analysis period of 2023 to 2032.
The key players operating in the global hemoperfusion market are includes Jafron Biomedical Co., Ltd., Kaneka Corporation, Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG, Toray Medical Co., Ltd., Asahi Kasei Medical Co., Ltd., NxStage Medical, Inc., CytoSorbents Corporation, and Spectral Medical Inc.
North America held the dominating position in hemoperfusion industry during the analysis period of 2023 to 2032.
Asia-Pacific region exhibited fastest growing CAGR for market of hemoperfusion during the analysis period of 2023 to 2032.
The current trends and dynamics in the hemoperfusion industry include increasing incidence of acute poisoning cases, growing prevalence of chronic kidney diseases, and rising demand for extracorporeal blood purification techniques.
The charcoal adsorption held the maximum share of the hemoperfusion industry.